- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04641091
Muscle Perfusion in Patients With PAD by Non-invasive MSOT
Cross-sectional Study of Muscle Perfusion in Patients With PAD by Non-invasive Multispectral Optoacoustic Tomography
Study Overview
Status
Intervention / Treatment
Detailed Description
Peripheral arterial occlusive disease (PAD) is one of the most common diseases of the elderly with an overall prevalence of about 3-10%. As life expectancy increases, new treatment concepts and new diagnostic procedures are needed. In addition to the possibility of endovascular treatment and open surgery, in some cases there is also the possibility of a conservative therapeutic approach, e.g. with medication.
To date, the only independent non-invasive validation of these treatment options is the measurement of macrocirculation in the form of Color-Coded Vascular Duplex Sonography (CCDS), the Ankle Brachial Index (ABI) or the measurement of walking distance. The S3 guideline for diagnosis, therapy and medical aftercare of PAD published 2015 by the DGA (Deutsche Gesellschaft für Angiologie und Gefäßmedizin [German Society for Angiology and Vascular Medicine]) recommends aftercare in the sense of clinical examinations, especially for patients after vascular surgery. For the validation measures already mentioned, however, there are not infrequent patient groups for which these methods provide only insufficient or unusable results (diabetes mellitus, terminal renal failure). In these cases, independent verification of the success of the therapy performed would have to be performed using angiography (digital subtraction angiography, CT angiography or MR angiography). However, this is not routinely performed in the respective patient populations due to the associated risks (including radiation exposure, contrast agent administration, invasiveness).
Multispectral Optoacoustic Tomography (MSOT) now provides a new non-invasive diagnostic tool that may be able to fill this diagnostic gap.
The aim of this cross-sectional study is to define an independent parameter using the MSOT method, which allows a statement about the current perfusion situation of the lower extremity and correlates with the angiography, which is considered the gold standard. For this purpose, patients of different PAD stages, who already underwent routinely angiographies in advance, will be included. In addition, a control group of healthy volunteers (prior angiography not obligatory) will be examined.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Erlangen, Germany, 91054
- University of Erlangen, Vascular Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with
- PAD IIa with indication for angiography
- PAD IIb with indication for angiography
- PAD III with indication for angiography
- PAD IV with indication for angiography
who come in for a routine presentation of the vascular surgery consultation hours.
And healthy volunteers:
- No PAD previously known
- No diabetes mellitus previously known
- No chronic renal insufficiency previously known
- No symptoms in the sense of a Claudicatio intermitten
- ABI with normal value
who are recruted by clinic notices.
Description
Inclusion criteria:
- Patients with manifest PAD stages II - IV according to Fontaine or category 1-6 according to Rutherford
- Adult (>18 years) persons who are able to give their consent
- Patients in whom angiography has been performed as part of routine diagnostics (independent of the study) or in accordance with current guidelines, or has been indicated and the patients has given consent
Exclusion criteria:
- Patients with PAD stage I according to Fontaine or category 0 according to Rutherford
- Underage persons
- Missing consent form
- Patients with manifest PAD in whom angiography is not indicated
- Exclusion due to safety concerns of the study physician (patient with a physical, mental or psychiatric illness which, in the opinion of the study physician, would compromise the safety of the patient or the quality of the data and thus make the patient an unsuitable candidate for the study)
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Study group 1
Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site) physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision |
non-invasive transcutaneous imaging of subcellular muscle components
|
Study group 2
Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site) physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision |
non-invasive transcutaneous imaging of subcellular muscle components
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Derivation of optimal diagnostic MSOT thresholds for hemoglobin
Time Frame: single time point (1 day)
|
Derivation of optimal diagnostic MSOT thresholds for hemoglobin through correlation with TASC classification for angiographic imaging as references for relevant stenosis/ occlusion in patients with PAD
|
single time point (1 day)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscular oxygenated/deoxygenated/total hemoglobin and the MSOT-values at a wavelength of 800nm before and after gait exposure
Time Frame: single time point (1 day)
|
Quantitative oxygenated/deoxygenated/total hemoglobin signal and signal at a wavelength of 800 nm (Units: arbitrary units (a.
u.)) derived by transcutaneous MSOT in patients with PAD before gait exposure compared to the signals after gait exposure
|
single time point (1 day)
|
Correlation of oxygenated/deoxygenated/total hemoglobin content and MSOT-values at a wavelength of 800 nm with the TASC-classification (angiography)
Time Frame: single time point (1 day)
|
Quantitative oxygenated/deoxygenated/total hemoglobin signal and signal at a wavelength of 800 nm(Units: arbitrary units (a.
u.)) derived by transcutaneous MSOT in patients with PAD correlated with the TASC-classification (angiography)
|
single time point (1 day)
|
Difference between oxygenated/deoxygenated hemoglobin before and after gait exposure
Time Frame: single time point (1 day)
|
Difference between quantitative oxygenated hemoglobin amount (Units: arbitrary units (a.
u.)) and quantitative deoxygenated hemoglobin amount (Units: arbitrary units (a.
u.)) derived by transcutaneous MSOT in patients with PAD before gait exposure compared to the amount after gait exposure
|
single time point (1 day)
|
Correlation of difference between oxygenated/deoxygenated hemoglobin with the TASC-classification (angiography)
Time Frame: single time point (1 day)
|
Difference between quantitative oxygenated hemoglobin amount (Units: arbitrary units (a.
u.)) and quantitative deoxygenated hemoglobin amount (Units: arbitrary units (a.
u.)) derived by transcutaneous MSOT in patients with PAD correlated with the TASC-classification (angiography)
|
single time point (1 day)
|
Muscular quantitative lipid/collagen signal fraction and the MSOT-values at a wavelength of 930 and 1064 nm
Time Frame: single time point (1 day)
|
Quantitative lipid/collagen signals and signals at 930 and 1064 nm (Units: arbitrary units (a.
u.)) derived by transcutaneous MSOT in patients with different clinical and angiographic PAD stages
|
single time point (1 day)
|
Correlation of acquired MSOT parameters with the CCDS flow profile and PSV
Time Frame: single time point (1 day)
|
Quantitative oxygenated/deoxygenated/total hemoglobin content and MSOT-values at a wavelength of 800 nm (Units: arbitrary units (a.
u.)) derived by transcutaneous MSOT in patients with PAD correlated with the flow profile and PSV of A. CFA and A. poplitea determined by CCDS
|
single time point (1 day)
|
Correlation of acquired MSOT parameters with the ABI
Time Frame: single time point (1 day)
|
Quantitative oxygenated/deoxygenated/total hemoglobin content and MSOT-values at a wavelength of 800 nm (Units: arbitrary units (a.
u.)) derived by transcutaneous MSOT correlated with the ABI
|
single time point (1 day)
|
Correlation of acquired MSOT parameters with the walking distance determined by treadmill examination
Time Frame: single time point (1 day)
|
Quantitative oxygenated/deoxygenated/total hemoglobin content and MSOT-values at a wavelength of 800 nm (Units: arbitrary units (a.
u.)) derived by transcutaneous MSOT correlated with the walking distance determined by treadmill examination
|
single time point (1 day)
|
Correlation of acquired MSOT parameters with the clinical severity of PAD
Time Frame: single time point (1 day)
|
Quantitative oxygenated/deoxygenated/total hemoglobin content and MSOT-values at a wavelength of 800 nm (Units: arbitrary units (a.
u.)) derived by transcutaneous MSOT correlated with the clinical severity of PAD according to Fontaine and Rutherford
|
single time point (1 day)
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Lange S, Diehm C, Darius H, Haberl R, Allenberg JR, Pittrow D, Schuster A, von Stritzky B, Tepohl G, Trampisch HJ. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Exp Clin Endocrinol Diabetes. 2004 Nov;112(10):566-73. doi: 10.1055/s-2004-830408.
- Alpert JS, Larsen OA, Lassen NA. Exercise and intermittent claudication. Blood flow in the calf muscle during walking studied by the xenon-133 clearance method. Circulation. 1969 Mar;39(3):353-9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MSOT_PAD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Multispectral Optoacustic Tomography (MSOT)
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruiting
-
Ulrich RotherPD Dr. med. Ferdinand Knieling, Department of pediatrics, University of Erlangen-NürnbergRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Intermittent ClaudicationGermany
-
University of Erlangen-Nürnberg Medical SchoolCompletedInflammatory Bowel Diseases | Digestive System DiseaseGermany
-
University of Erlangen-Nürnberg Medical SchoolRecruitingPompe Disease (Late-onset) | Pompe Disease | Pompe's Disease Juvenile Onset | Pompe Disease Infantile-OnsetGermany
-
Children's Hospital of Eastern OntarioNot yet recruitingNeuromuscular Diseases
-
iThera Medical GmbHEuropean CommissionSuspendedInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisGermany, Italy
-
University Hospital ErlangenDepartment of Pediatrics and Adolescent Medicine, University Hospital Erlangen... and other collaboratorsActive, not recruitingPeripheral Arterial Disease | Peripheral Vascular DiseasesGermany
-
University of Erlangen-Nürnberg Medical SchoolCompletedMuscular Diseases | Spinal Muscular AtrophyGermany
-
University of Erlangen-Nürnberg Medical SchooliThera Medical GmbHCompletedCrohn's Disease | Ulcerative Colitis | IBDGermany
-
Memorial Sloan Kettering Cancer CenterRecruitingMelanoma | Breast CancerUnited States, Germany